Dr Mason and colleagues from the United Kingdom established if H pylori eradication in long-term proton pump inhibitors (PPI) users is cost-effective.
The team assigned 183 long-term PPI-using patients testing positive for H pylori to true or placebo eradication therapy.
Patients provided 2-year resource data, and 1-year symptom severity scores.
A within-trial cost effectiveness analysis was conducted from a British health service perspective.
|Upper gastrointestinal endoscopies fell by 15%|
|Alimentary Pharmacology & Therapeutics|
The researchers found significant reductions in resource use on comparing eradication with placebo.
After 2 years, PPI prescriptions fell by 3%, and clinician general practice consultations by 2%.
The team noted that upper gastrointestinal endoscopies fell by 15%, clinician gastrointestinal-related home visits by 20%, and abdominal ultrasound scans fell by 20%.
The team found that average net savings per patient were £93 after costs of detection, and eradication had been deducted.
At 1 year, Leeds Dyspepsia Questionnaire symptoms fell by 3, and quality-of-life measures improved favoring eradication.
Dr Mason’s team concluded, “H pylori eradication in infected, long-term PPI users is an economically dominant strategy, significantly reducing overall healthcare costs and symptom severity.”